8-K
filed June 2, 2026, 7:05 AM ET
ticker TVTX
CIK 0001438533
M&A
confidence high
sentiment positive
materiality 0.80
Travere licenses Everest's BTK inhibitor with $112.5M upfront, up to $1.03B milestones
Travere Therapeutics, Inc.
- Exclusive license for civorebrutinib (BTK inhibitor) outside China and select East/Southeast Asia countries.
- Upfront payment of $112.5M; potential milestones up to ~$1.03B across up to five indications.
- Tiered royalties from high single-digit to double-digit percentages on net sales in Territory.
- Travere responsible for development and commercialization in Territory; global trial costs shared with Everest.
- Deal effective upon HSR clearance; Travere can terminate and get upfront refund if tech transfer fails.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001193125-26-252474
- form_type
- 8-K
- ticker
- TVTX
- cik
- 0001438533
- company_name
- Travere Therapeutics, Inc.
- filed_at
- 2026-06-02T11:05:07+00:00
- discovered_at
- 2026-06-02T11:10:00.234617+00:00
- generated_at
- 2026-06-02T11:12:43.447413+00:00
- sec_items
- ["1.01", "9.01"]
- event_type
- m_and_a
- sentiment
- positive
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001193125-26-252474
- json_url
- https://secwatch.observer/filing/0001193125-26-252474.json
- markdown_url
- https://secwatch.observer/filing/0001193125-26-252474.md
- text_url
- https://secwatch.observer/filing/0001193125-26-252474.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/0001193125-26-252474-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1438533/000119312526252474/d107618d8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
WLY
Wiley acquires Emerald Publishing for $452M; adds ~500 journals, expected accretive in year one
JOHN WILEY & SONS, INC.
June 2, 2026, 8:30 AM ET
m_and_a
Items 1.01, 2.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
entered into an Equity Purchase Agreement (the "Purchase Agreement") with CIG Emerald Midco LLC, a Delaware limited liability company (the "Seller"), and CIG Emerald Holding LLC, a Delaware limited liability company ("Emerald Holding"), pursuant to which Buyer acquired from the Seller all of the issued and outstanding equity securities of Emerald Holding (the "Transaction") in exchange for GBP £337.5 million (approximately $452 million)
Filing page
SEC filing
ARXS
Arxis agrees to acquire Omnetics in ~$770M all-stock deal; closes MagCanica acquisition
Arxis, Inc.
June 2, 2026, 7:00 AM ET
m_and_a
Items 1.01, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
On May 29, 2026, Arxis, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Orion Merger Sub, Inc., a Minnesota corporation and a wholly owned subsidiary of Arxis (the “Merger Sub”), Omnetics Connector Corporation, a Minnesota corporation (“Omnetics”), and Gary Jacobs, President of Omnetics, in his capacity as shareholder representative (the “Shareholder Representative”).
Filing page
SEC filing
HIMS
Hims & Hers completes acquisition of Eucalyptus; reaffirms 2030 targets of $6.5B revenue
Hims & Hers Health, Inc.
June 2, 2026, 6:02 AM ET
m_and_a
Items 1.01, 2.03, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
On May 29, 2026, Hims & Hers Health, Inc. (the “ Company ”), as borrower, entered into Amendment No. 3 (the “ Amendment ”) to the Revolving Credit and Guaranty Agreement, dated as of February 18, 2025 (as amended by that certain Amendment No. 1 to the Revolving Credit and Guaranty Agreement, dated as of June 25, 2025, that certain Amendment No. 2 to the Revolving Credit and Guaranty Agreement, dated as of May 7, 2026, and as amended by this Amendment, the “ Credit Agreement ”), by among the Company, the subsidiary borrowers and the guarantors from time to time party thereto, the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.
Filing page
SEC filing
HNRG
Hallador Energy acquires 460 MW Siemens turbines for $350M to advance Merom gas project
HALLADOR ENERGY CO
June 2, 2026, 6:00 AM ET
m_and_a
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
On May 30, 2026, Hallador Energy Company (the “Company”) entered into an Asset Purchase Agreement (the “APA”) with Energy World Corporation Ltd., incorporated in Australia (“Seller”), to acquire approximately 460 MW of Siemens gas turbines, generators, a steam turbine, and ancillary equipment (the “Equipment”) for an aggregate purchase price of $350 million.
Filing page
SEC filing
Enviri II Corp
New Enviri completes spin-off; starts trading June 2 under NVRI; ~$1.2B revenue, ~$140M EBITDA
Enviri II Corp
June 1, 2026, 5:18 PM ET
m_and_a
Items 1.01, 2.03, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
On June 1, 2026, New Enviri entered into a transition services agreement (the “Transition Services Agreement”) with CLEH pursuant to which New Enviri will provide certain services to CLEH on an interim, transitional basis.
Filing page
SEC filing
TACH
Titan Acquisition Corp enters $800M deal to combine with OpenPayd
Titan Acquisition Corp.
June 1, 2026, 5:15 PM ET
m_and_a
Items 1.01, 7.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
On June 1, 2026, Titan Acquisition Corp, a Cayman Islands exempted company (“Titan”), entered into a Business Combination Agreement (the “Business Combination Agreement”), by and among OpenPayd Global Holdings Limited, a Cayman Islands exempted company (“PubCo”), Titan Acquisition Sponsor Holdco LLC, a Delaware limited liability company (the “Sponsor”), solely in its capacity as the Purchaser Representative, OpenPayd Holdings Limited, a company limited by shares incorporated in England and Wales (“Company”), Ozan Özerk, solely in his capacity as the Company Shareholders Representative, and the shareholders of the Company party thereto (collectively, the “Parties”).
Filing page
SEC filing
RPAY
REPAY closes $372M acquisition of KUBRA, funded with new $500M term loan
Repay Holdings Corp
June 1, 2026, 4:14 PM ET
m_and_a
Items 1.01, 2.01, 1.02, 9.01, 2.03, 7.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
On June 1, 2026 (the “Closing Date”), Repay Holdings Corporation (the “Company” or “REPAY”), its wholly owned subsidiary, Hawk Parent Holdings LLC, a Delaware limited liability company (the “Borrower”) and certain subsidiaries of the Company party thereto, as guarantors, entered into a Credit Agreement (the “Credit Agreement”) with certain financial institutions party thereto, as lenders, and Truist Bank, as administrative agent.
Filing page
SEC filing
EEX
Apollo Funds acquire Emerald (EEX) for $5.03/sh (42% premium); combine with Questex
Emerald Holding, Inc.
May 11, 2026, 7:59 PM ET
m_and_a
Items 1.01, 5.07, 8.01, 9.01
same fact type: material_agreement
same SEC item: 1.01, 9.01
same event type: m_and_a
similar materiality
This filing
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive license to the Company for the development and commercialization of civorebrutinib
Comparable filing
On May 9, 2026, Emerald Holding, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Emma Buyer, LLC, a Delaware limited liability company (“ Parent ”), and Emma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent (“ Merger Sub ”).
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.